Literature DB >> 18615103

Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.

J K Lamba, S Pounds, X Cao, J R Downing, D Campana, R C Ribeiro, C-H Pui, J E Rubnitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18615103      PMCID： PMC2659556          DOI： 10.1038/leu.2008.185

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.

Authors:  Roland B Walter; Ted A Gooley; Vincent H J van der Velden; Michael R Loken; Jacques J M van Dongen; David A Flowers; Irwin D Bernstein; Frederick R Appelbaum
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

2.  Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.

Authors:  Jatinder K Lamba; Kristine Crews; Stanley Pounds; Erin G Schuetz; Jessica Gresham; Varsha Gandhi; William Plunkett; Jeffrey Rubnitz; Raul Ribeiro
Journal:  J Pharmacol Exp Ther       Date:  2007-09-12       Impact factor: 4.030

3.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Authors:  P F Bross; J Beitz; G Chen; X H Chen; E Duffy; L Kieffer; S Roy; R Sridhara; A Rahman; G Williams; R Pazdur
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

Review 4.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse.

Authors:  E L Sievers
Journal:  Expert Opin Biol Ther       Date:  2001-09       Impact factor: 4.388

5.  Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.

Authors:  J A Dowell; J Korth-Bradley; H Liu; S P King; M S Berger
Journal:  J Clin Pharmacol       Date:  2001-11       Impact factor: 3.126

6.  The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score.

Authors:  O Legrand; J Y Perrot; M Baudard; A Cordier; R Lautier; G Simonin; R Zittoun; N Casadevall; J P Marie
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

7.  Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove.

Authors:  N Ikemoto; R A Kumar; T T Ling; G A Ellestad; S J Danishefsky; D J Patel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

8.  Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia.

Authors:  Mary Buckwalter; James A Dowell; Joan Korth-Bradley; Boris Gorovits; Philip R Mayer
Journal:  J Clin Pharmacol       Date:  2004-08       Impact factor: 3.126

9.  Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia.

Authors:  Elaine Coustan-Smith; Raul C Ribeiro; Jeffrey E Rubnitz; Bassem I Razzouk; Ching-Hon Pui; Stanley Pounds; Martin Andreansky; Frederick G Behm; Susana C Raimondi; Sheila A Shurtleff; James R Downing; Dario Campana
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998
  9 in total
  15 in total

1.  Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.

Authors:  Carol O'Hear; Hiroto Inaba; Stanley Pounds; Lei Shi; Gary Dahl; W Paul Bowman; Jeffrey W Taub; Ching-Hon Pui; Raul C Ribeiro; Elaine Coustan-Smith; Dario Campana; Jeffrey E Rubnitz
Journal:  Cancer       Date:  2013-09-04       Impact factor: 6.860

2.  CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

Authors:  Jatinder K Lamba; Lata Chauhan; Miyoung Shin; Michael R Loken; Jessica A Pollard; Yi-Cheng Wang; Rhonda E Ries; Richard Aplenc; Betsy A Hirsch; Susana C Raimondi; Roland B Walter; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2017-06-23       Impact factor: 44.544

3.  CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Authors:  Lata Chauhan; Miyoung Shin; Yi-Cheng Wang; Michael Loken; Jessica Pollard; Richard Aplenc; Betsy A Hirsch; Susana Raimondi; Rhonda E Ries; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi; Jatinder K Lamba
Journal:  JCO Precis Oncol       Date:  2019-05-23

4.  Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Authors:  Mohammed Gbadamosi; Soheil Meshinchi; Jatinder K Lamba
Journal:  Future Oncol       Date:  2018-07-24       Impact factor: 3.404

5.  Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.

Authors:  Leslie Mortland; Todd A Alonzo; Roland B Walter; Robert B Gerbing; Amit K Mitra; Jessica A Pollard; Michael R Loken; Betsy Hirsch; Susana Raimondi; Janet Franklin; Stanley Pounds; Xueyuan Cao; Jeffrey E Rubnitz; Raul C Ribeiro; Alan Gamis; Soheil Meshinchi; Jatinder K Lamba
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

6.  A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.

Authors:  Priyanka Nair-Gupta; Michael Diem; Dara Reeves; Weirong Wang; Robert Schulingkamp; Katrin Sproesser; Bethany Mattson; Bradley Heidrich; Mark Mendonça; Jocelin Joseph; Jocelyn Sendecki; Brad Foulk; Gerald Chu; Damien Fink; Qun Jiao; Sheng-Jiun Wu; Kathryn Packman; Yusri Elsayed; Ricardo Attar; François Gaudet
Journal:  Blood Adv       Date:  2020-03-10

Review 7.  Biological Hallmarks of Cancer in Alzheimer's Disease.

Authors:  Kelly N H Nudelman; Brenna C McDonald; Debomoy K Lahiri; Andrew J Saykin
Journal:  Mol Neurobiol       Date:  2019-04-16       Impact factor: 5.590

8.  CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents.

Authors:  Ioannis Papageorgiou; Michael R Loken; Lisa Eidenschink Brodersen; Mohammed Gbadamosi; Geoffrey L Uy; Soheil Meshinchi; Jatinder K Lamba
Journal:  Leuk Lymphoma       Date:  2019-02-05

9.  Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia.

Authors:  Manasi Malik; Joe Chiles; Hualin S Xi; Christopher Medway; James Simpson; Shobha Potluri; Dianna Howard; Ying Liang; Christian M Paumi; Shubhabrata Mukherjee; Paul Crane; Steven Younkin; David W Fardo; Steven Estus
Journal:  Hum Mol Genet       Date:  2015-03-11       Impact factor: 5.121

10.  Altered neutrophil immunophenotypes in childhood B‑cell precursor acute lymphoblastic leukemia.

Authors:  Elen Oliveira; Thiago S Bacelar; Juana Ciudad; Maria Cecília M Ribeiro; Daniela R N Garcia; Lukasz Sedek; Simone F Maia; Daniel B Aranha; Indyara C Machado; Arissa Ikeda; Bianca F Baglioli; Nathalia Lopez-Duarte; Lisandra A C Teixeira; Tomasz Szczepanski; Maria Luiza M Silva; Marcelo G P Land; Alberto Orfao; Elaine S Costa
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.